Janux Therapeutics, Inc. (JANX): Price and Financial Metrics


Janux Therapeutics, Inc. (JANX): $11.72

0.72 (+6.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add JANX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

JANX Stock Price Chart Interactive Chart >

Price chart for JANX

JANX Price/Volume Stats

Current price $11.72 52-week high $37.99
Prev. close $11.00 52-week low $9.39
Day low $11.28 Volume 31,100
Day high $11.86 Avg. volume 80,227
50-day MA $12.72 Dividend yield N/A
200-day MA $19.02 Market Cap 487.89M

Janux Therapeutics, Inc. (JANX) Company Bio


Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.


JANX Latest News Stream


Event/Time News Detail
Loading, please wait...

JANX Latest Social Stream


Loading social stream, please wait...

View Full JANX Social Stream

Latest JANX News From Around the Web

Below are the latest news stories about Janux Therapeutics Inc that investors may wish to consider to help them evaluate JANX as an investment opportunity.

Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

SAN DIEGO, January 05, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.

Yahoo | January 5, 2022

Janux Therapeutics (NASDAQ:JANX) Shares Down 13.8%

Janux Therapeutics, Inc. (NASDAQ:JANX)s stock price traded down 13.8% during mid-day trading on Tuesday . The company traded as low as $17.07 and last traded at $17.07. 2,441 shares traded hands during trading, a decline of 99% from the average session volume of 176,950 shares. The stock had previously closed at $19.80. Separately, Zacks Investment []

Dakota Financial News | December 16, 2021

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | December 11, 2021

Janux Therapeutics, Inc.s (NASDAQ:JANX) Lock-Up Period Will End Tomorrow

Janux Therapeutics (NASDAQ:JANX) lock-up period is set to expire on Wednesday, December 8th. Janux Therapeutics had issued 11,400,000 shares in its public offering on June 11th. The total size of the offering was $193,800,000 based on an initial share price of $17.00. After the end of Janux Therapeutics lock-up period, major shareholders and company insiders [] The post Janux Therapeutics, Inc.s (NASDAQ:JANX) Lock-Up Period Will End Tomorrow appeared first on ETF Daily News .

ETF Daily News | December 7, 2021

Janux Therapeutics leads list of IPO stocks set to see lockup expirations this week

No summary available.

Seeking Alpha | December 6, 2021

Read More 'JANX' Stories Here

JANX Price Returns

1-mo 8.62%
3-mo -35.25%
6-mo -34.93%
1-year N/A
3-year N/A
5-year N/A
YTD -40.60%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3949 seconds.